• Plexus Corp. (NasdaqGS: PLXS) was recently removed from several Russell value and small-cap benchmarks, including the Russell 3000 Value, Russell 2000 Value, and related composite indices, following the latest index reconstitution.
• This broad index removal can trigger forced buying and selling by funds that track these benchmarks, potentially reshaping who owns the stock and how it trades over time.
• Next, we’ll examine how Plexus’s removal from multiple Russell value benchmarks may influence its existing investment narrative and risk profile.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Plexus Investment Narrative Recap

To own Plexus, you need to believe in its role as a high value partner in complex electronics across healthcare, industrial and aerospace and defense, with engineering depth and a global footprint that can keep winning long duration programs. The broad removal from Russell value and small cap indices mainly affects who holds the shares, not how Plexus runs its business, so it does not materially change the near term catalysts or core operating risks.

The most relevant recent announcement alongside the Russell deletions is Plexus’s new US$500 million revolving credit facility, expandable to US$750 million, running to 2031. That financing gives the company additional flexibility to fund capacity, automation and working capital even if index driven flows create short term share price volatility, tying directly into both the ramp up catalysts and the execution and margin pressure risks already on investors’ radar.

Yet, while the index changes may feel technical, investors should still watch how they intersect with Plexus’s customer concentration and program timing risks...

Plexus' narrative projects $6.0 billion revenue and $278.4 million earnings by 2029. This requires 11.8% yearly revenue growth and about a $90.9 million earnings increase from $187.5 million today.

Uncover how Plexus' forecasts yield a $280.75 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue above US$5.0 billion and earnings near US$257 million by 2029, which is far more bullish than the cautious view that Plexus’s working capital build and potential Aerospace and Defense program delays could strain cash flow and growth, especially now that broad index removal might prompt you to reconsider how confident you are in either scenario.

Explore 2 other fair value estimates on Plexus - why the stock might be worth as much as $280.75!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Plexus research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Plexus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Plexus' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 41 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.